Cited by 63SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAsthma and respiratory diseases

Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective

Open access
Hosoki, Koa, Chakraborty, Abhijit, Sur, Sanjiv·2020·Journal of Allergy and Clinical Immunology

Abstract

The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being "immune" to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration-approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2020.05.033

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • It is currently unclear if asthma is indeed a risk factor for COVID-19 complications, and studies so far have not conclusively observed the expected increase in incidence.

    “However, it is currently unclear if asthma is indeed a risk factor for COVID-19 complications (Hosoki et al., 2020), and studies so far have not conclusively observed the expected increase in incidence.”

    From Viral Infections, the Microbiome, and Probiotics (2021) · cites this paper as Hosoki et al., 2020

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 203 · Cited by 63

Research works printed but not linked: 1

  1. [19]National Institutes of Health COVID-19 treatment guidelines Available at: https://covid19treatmentguidelines.nih.gov/introduction/ Accessed April 19, 2020 34003615

Authors
Hosoki, K., Chakraborty, A., & Sur, S.
Affiliations
Baylor College of Medicine (US)
Corresponding author
Sur, Sanjiv
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2020-08
Volume
146
Issue
2
Pages
285-299
ISSN
0091-6749 (ISSN-L)
OpenAlex
W3038765308
Cited by
63
References
203
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 10 · 2022: 10 · 2021: 26 · 2020: 11
FWCI
0.67
Type
journal article
Language
en
Open access
Locations
  • Journal of Allergy and Clinical Immunology (acceptedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
  • National Heart, Lung, and Blood Institute (3R01HL145477-01S1)
  • U.S. Department of Defense (PR171425 W81XWH-18-1-0743)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
Keywords
COVID-19 pandemic, SARS-CoV-2, angiotensin-converting enzyme 2 receptor, spike protein receptor-binding domain, TMPRSS2, virus transmission, asymptomatic transmission, PCR testing, antibody detection, allergic rhinitis, asthma, asthma endotypes, COVID-19 risk factors, drug repurposing, remdesivir, pandemic mitigation strategies, face masks, social distancing
MeSH terms
Betacoronavirus, Physical Distancing, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, COVID-19 Testing, COVID-19 Drug Treatment, Adenosine Monophosphate, Age Factors, Alanine, Antiviral Agents, Asthma, Clinical Trials as Topic, Humans, Peptidyl-Dipeptidase A, Masks, Pneumonia, Viral, Quarantine, Receptors, Virus, Severity of Illness Index, Prevalence, Coronavirus Infections, Clinical Laboratory Techniques, Drug Repositioning, Pandemics, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review